Bladder Cancer

Papers
(The median citation count of Bladder Cancer is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Single-cell RNA sequencing and spatial transcriptome analysis in bladder cancer: Current status and future perspectives21
Association of CCL2/CCR2 gene polymorphisms and bladder cancer risk in a hispanic-rich US population19
Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer18
Predicting Recurrence and Progression in Patients with Non-Muscle-Invasive Bladder Cancer: Systematic Review on the Performance of Risk Stratification Models12
Metastasis-directed radiotherapy for oligometastatic urothelial carcinoma of the bladder and upper tract11
Patterns of care and associated social determinants of health in the definitive treatment of localized muscle-invasive bladder cancer patients11
Comparison of Robotic vs Open Cystectomy: A Systematic Review10
No Association Between BCG Instillations and COVID-19 Incidence in a Dutch Non-Muscle Invasive Bladder Cancer Cohort10
Computational pathology in bladder cancer: A scoping review9
Standard vs extended lymphadenectomy for muscle invasive bladder cancer8
Clinical Trials Corner Issue 9(2)8
Urologists and Advanced Practice Providers Evaluating Hematuria8
Intravesical instillation of chemotherapy before surgery for upper tract urothelial cancer8
Management of bladder cancer in kidney transplant recipients: A narrative review7
Evaluation of the Effects of Opium on the Expression of SOX2 and OCT4 in Wistar Rat Bladder6
Clinical trials corner issue 12(1)6
Development of an extended version of GALEAS bladder: Detection of FGFR3 fusions in urine and associations between genomic alterations and gene expression6
Orthotopic bladder cancer preclinical models: Comprehensive review and technique optimization6
A New Standard of Care for Bladder Cancer5
Expression of PD-1 and PD-L1 in BCG-treated NMIBC5
Clinical Trials Corner Issue 10(2)5
Analysis of sarcopenia indicators on survival prediction undergoing radical cystectomy4
Non-Muscle Invasive Bladder Cancer: Many More Patients Die With It Than Of It4
Systemic induction therapy in patients with locally advanced or node-positive urothelial carcinoma: Evaluating treatment outcomes4
Organoid models in bladder cancer: From bench to bedside?4
Proceedings of the first international NMIBC consensus classification meeting4
Y Chromosome Loss and Bladder Cancer3
Challenging Cases in Urothelial Cancer: Case 333
Commentary on Novitas LCD3
Challenging Cases in Urothelial Cancer: Case 263
Does Blue Light Cystoscopy Reduce Recurrences of Non-Muscle Invasive Bladder Cancer?3
Immune Checkpoint Inhibitors in Metastatic Bladder and Other Solid Malignancies: How Long is Enough?3
The role of blue light cystoscopy and additional operative evaluations during first surveillance after induction therapy for high-risk NMIBC3
Molecular Basis of Tumorigenesis of Bladder Cancer and Emerging Concepts in Developing Therapeutic Targets3
Switch Maintenance Therapy for Metastatic Urothelial Carcinoma2
Interdisciplinary Swiss consensus recommendations for follow-up after radical cystectomy and trimodal treatment for muscle-invasive bladder cancer2
Urothelial carcinoma and the potential clinical application of urinary extracellular vesicles: Current Status and prospects2
Platinum-based chemotherapy rechallenge or enfortumab vedotin after maintenance avelumab or pembrolizumab for locally advanced or metastatic urothelial carcinoma2
Circulating tumor DNA–guided adjuvant immunotherapy in muscle-invasive bladder cancer2
Efficacy of Antibody Drug Conjugates Alone and in Combination with other Agents in Metastatic Urothelial Carcinoma: A Scoping Review2
NK Cell-Targeted Immunotherapies in Bladder Cancer: Beyond Checkpoint Inhibitors2
Physical Activity and Health-related Quality of Life from Diagnosis to One Year After Radical Cystectomy in Patients with Bladder Cancer: A Longitudinal Cohort Study2
Novel Delivery Mechanisms for Existing Systemic Agents and Emerging Therapies in Bladder Cancer2
Adjuvant Chemotherapy Plus Radiotherapy versus Chemotherapy Alone for Locally Advanced Bladder Cancer after Radical Cystectomy2
Electromotive Drug Administration Chemotherapy with Mitomycin C Versus Bacillus Calmette-Guerin for the Treatment of Non-Muscle Invasive Bladder Cancer2
Longitudinal Analysis of Bladder Cancer-Specific Mortality Trends in the United States2
Advancements in systemic therapy for muscle-invasive bladder cancer: A systematic review from the beginning to the latest updates2
Comparative Analysis of Very Reduced vs Full Dose BCG Treatment for High-Risk Non-Muscle Invasive Bladder Cancer: A Contemporary Experience from Chile2
Challenging Cases in Urothelial Cancer: Case 272
Patterns of Smoking Cessation Strategies and Perception of E-cigarette Harm Among Bladder Cancer Survivors2
Editorial Concerning “The Association Between Diabetes Medication Use and Tumour Characteristics at Diagnosis in Patients with Urothelial Carcinoma: A Retrospective Registry-Based Study”2
Impact of neighborhood deprivation on bladder cancer outcomes: A regional analysis1
Neoadjuvant Intravesical Chemotherapy for Non-muscle Invasive Bladder Cancer1
A Multicenter Study of 2-year Outcomes Following Hyperthermia Therapy with Mitomycin C in Treating Non-Muscle Invasive Bladder Cancer: HIVEC-E1
Factors Influencing Patient Decision-Making in the Treatment of Muscle-Invasive Bladder Cancer1
Challenging Cases in Urothelial Cancer: Case 28: Lynch Syndrome1
Is There A Benefit of Restaging Transurethral Resection of Bladder Tumor Prior to Radical Cystectomy With or Without Neoadjuvant Chemotherapy?1
The Evolution of Nadofaragene Firadenovec: A Review and the Path Forward1
An Association Study of Germline Variants in Bladder Cancer-Related Genes with the Prognosis of Non-Muscle Invasive Bladder Cancer1
Neoadjuvant chemotherapy for high-risk upper tract urothelial cancer1
When a ‘routine’ TURBT is not routine: Lessons from SEER-medicare1
Serum metabolomic analysis identified serum biomarkers predicting tumour recurrence after Bacillus Calmette–Guérin therapy in patients with non-muscle invasive bladder cancer1
Multi-Center Assessment of Lymph-Node Density and Nodal-Stage to Predict Disease-Specific Survival in Patients with Bladder Cancer Treated by Radical Cystectomy1
Challenging Cases in Urothelial Cancer: Case 30: Rare Complication of BCG1
Systematic review: The role of bicarbonate therapy after urinary diversion1
Clinical Trials Corner Issue 10(1)1
Abstracts selected for poster presentation [listed in alphabetical order by presenter]1
Induction and characterization of neoplastic bladder tumors in a transgenic porcine model1
BCG in Immunocompromised Patients: Is it effective? Is it safe?1
Neoadjuvant Cisplatin, Gemcitabine, and Docetaxel in Sarcomatoid Bladder Cancer: Clinical Activity and Whole Transcriptome Analysis1
BCG therapy for bladder cancer: Exploring patient experiences and concerns through artificial intelligence-based social media analysis1
PARP Inhibitors for Metastatic Urothelial Carcinoma: A Systematic Review of Efficacy and Safety1
Impact of Adjuvant Gemcitabine Containing Chemotherapy Following Radical Nephroureterectomy for Patients with Upper Tract Urothelial Carcinoma: Results from a Propensity-Score Matched Cohort Study1
What is a Bladder Cancer Molecular Subtype?1
Clinical Trials Corner Issue 9(4)1
Higher resilience in radical cystectomy patients is associated with improved health related quality of life post-operatively1
0.49642109870911